Pharmaceutical
Avectas: Engineering the Future of Cell Therapy Manufacturing
Recognizing the critical industry bottleneck in scalable cell therapy production, Avectas has announced a landmark collaboration with CCRM and OmniaBio to evaluate its innovative manufacturing platform.
Pharmaceutical
The Weight-Loss Drug Boom: Novo Nordisk's €432 Million Athlone Expansion
Novo Nordisk commits €432 million to upgrade its Athlone facility, expanding manufacturing capacity for oral GLP-1 weight-loss and diabetes treatments.
Pharmaceutical
From Powerhouse to Pioneer: How Ireland's Life Science Sector Is Pivoting from Manufacturing to an R&D-Led Innovation Hub in 2026
An in-depth analysis of Ireland's National Life Science Innovation Strategy in 2026. We examine the structural challenges of this transition-including specialised R&D infrastructure, the acute talent shortage in cell and gene therapies (CGT), and how digital compliance tools like Priya LifePDF streamline the transition.
Pharmaceutical
Why Ireland Remains the Global Pharma Hub: Analyzing the Historic $6.6 Billion Eli Lilly Tax Disclosure
The June 2026 country-by-country disclosures revealed that Eli Lilly paid $6.6 billion in Irish corporation tax-double its US federal liability. We analyze why Ireland remains the ultimate hub for global pharma despite the OECD 15% minimum tax.
Pharmaceutical
How the Iran Conflict Is Disrupting Ireland’s Pharmaceutical Industry and Why It Matters Globally.
Middle East air route disruptions are raising costs and delaying Ireland’s pharma exports, impacting global medicine supply chains.
Pharmaceutical
Ireland’s Pharmaceutical Export Decline in 2026: A Data-Driven Analysis of Emerging Trade Shifts
Ireland’s pharma exports fell 35% in Jan 2026, driven by a sharp decline in US shipments. Explore causes, trends, and global life sciences impact.